10x Genomics Consensus Price Target Raised 10.70% to $53.33
The average one-year price target for 10x Genomics (NASDAQGS:TXG) has been revised to $53.33 / share from $48.18 dated August 25, 2026, an increase of 10.70%. These figures are aggregate analyst targets compiled from institutional researchers and do not constitute a recommendation by Fintel.
The latest analyst targets range from a low of $40.40 to a high of $73.50 / share. The mean target of $53.33 was recorded on September 15, 2026 and is the highest among the observed twelve-month mean targets; the lowest observed twelve-month mean target was $15.08 on November 9, 2025. Prior mean targets include $48.18 on August 28, 2026, $40.96 on August 5, 2026, and $28.17 on June 30, 2026. Since the 90-day baseline date of June 8, 2026 the mean target has changed by +102.90%.
The current target range width is $33.10 versus the prior width of $48.05 (change -31.11%). The current median target is $51.00, producing a mean-median gap of $2.33.
The average price target represents a decrease of 23.93% from the latest reported closing price of $70.11 / share, recorded on September 14, 2026. The stock closed at $70.11 on September 14, 2026, representing a one-week price change of +11.91% from a baseline close of $62.65 on September 4, 2026 and a one-month price change of +25.00% from a baseline close of $56.09 on August 14, 2026.
10x Genomics, Inc. operates in the biotechnology industry. In its latest earnings report on August 6, 2026, the company reported actual EPS of -0.14 versus estimated EPS of -0.246. Actual revenue was 151,036,000.00 compared to estimated 148,255,516.00, a revenue surprise of +1.88%.
Recent analyst actions include UBS maintaining its Neutral rating on September 9, 2026 and RBC Capital initiating coverage with a Sector Perform rating on September 1, 2026. As of September 1, 2026 the recommendation breakdown was 5 strong buy, 4 buy, and 11 hold (45.0% positive recommendations, 55.0% hold recommendations).
Within its classified GICS sub-industry of Asset Management & Custody Banks (31 companies), 10 experienced raised targets, 4 were lowered, and 17 remained unchanged. The sub-industry median revision percent was 0.00% with a median implied change percent of +18.83%.
| Company name | Target revision | Implied change |
|---|---|---|
| Illumina | +3.77% | -1.40% |
| Pacific Biosciences of California | -5.87% | +62.98% |
| Standard BioTools | 0.00% | +126.99% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.